Capricor Therapeutics, Inc. CAPR
We take great care to ensure that the data presented and summarized in this overview for CAPRICOR THERAPEUTICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CAPR
View all-
Vanguard Group Inc Valley Forge, PA2.21MShares$12.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$9.17 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA962KShares$5.41 Million0.0% of portfolio
-
State Street Corp Boston, MA801KShares$4.51 Million0.0% of portfolio
-
Morgan Stanley New York, NY552KShares$3.11 Million0.0% of portfolio
-
Pier Capital, LLC Stamford, CT497KShares$2.8 Million0.62% of portfolio
-
J. Goldman & CO LP New York, NY482KShares$2.71 Million0.1% of portfolio
-
Dg Capital Management, LLC New York, NY470KShares$2.65 Million1.36% of portfolio
-
National Bank Of Canada398KShares$2.24 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY356KShares$2 Million0.0% of portfolio
Latest Institutional Activity in CAPR
Top Purchases
Top Sells
About CAPR
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Insider Transactions at CAPR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2025
|
Linda Marban CHIEF EXECUTIVE OFFICER |
SELL
Other acquisition or disposition
|
Direct |
12,500
-5.59%
|
-
|
|
Mar 03
2025
|
Linda Marban CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+10.06%
|
$25,000
$1.39 P/Share
|
|
Mar 03
2025
|
George W Dunbar Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+6.22%
|
$750
$1.39 P/Share
|
|
Mar 03
2025
|
Frank Litvack |
SELL
Payment of exercise price or tax liability
|
Direct |
2,543
-1.92%
|
$33,059
$13.67 P/Share
|
|
Mar 03
2025
|
Frank Litvack |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.88%
|
$25,000
$1.39 P/Share
|
|
Mar 03
2025
|
Anthony Bergmann CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+23.31%
|
$2,500
$1.39 P/Share
|
|
Feb 27
2025
|
Earl M Collier Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+1.29%
|
$750
$1.39 P/Share
|
|
Jan 02
2025
|
Anthony Bergmann CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,342
+36.87%
|
-
|
|
Dec 13
2024
|
Karen Krasney EVP, GENERAL COUNSEL |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+22.19%
|
$8,000
$1.39 P/Share
|
|
Dec 03
2024
|
Frank Litvack |
BUY
Exercise of conversion of derivative security
|
Indirect |
20,391
+30.59%
|
$20,391
$1.1 P/Share
|
|
Sep 20
2024
|
Nippon Shinyaku CO LTD |
BUY
Open market or private purchase
|
Direct |
2,798,507
+28.3%
|
$13,992,535
$5.36 P/Share
|
|
Aug 07
2024
|
David B Musket |
BUY
Exercise of conversion of derivative security
|
Direct |
34,000
+29.39%
|
$34,000
$1.39 P/Share
|
|
Apr 23
2024
|
Earl M Collier Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+34.54%
|
$30,000
$1.39 P/Share
|
|
Apr 23
2024
|
David B Musket |
BUY
Exercise of conversion of derivative security
|
Direct |
16,156
+25.3%
|
$16,156
$1.39 P/Share
|
|
Oct 23
2023
|
Anthony Bergmann CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,178
+47.77%
|
$2,178
$1.39 P/Share
|
|
Oct 12
2023
|
David B Musket |
BUY
Open market or private purchase
|
Direct |
410
+1.28%
|
$820
$2.75 P/Share
|
|
Oct 10
2023
|
Earl M Collier Jr |
BUY
Open market or private purchase
|
Direct |
10,000
+27.13%
|
$20,000
$2.83 P/Share
|
|
Oct 09
2023
|
David B Musket |
BUY
Open market or private purchase
|
Direct |
5,083
+14.04%
|
$10,166
$2.82 P/Share
|
|
Oct 06
2023
|
Paul Gisbert Auwaerter |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$10,000
$2.84 P/Share
|
|
Oct 04
2023
|
David B Musket |
BUY
Open market or private purchase
|
Direct |
2,500
+8.76%
|
$5,000
$2.9 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 82.4K shares |
|---|---|
| Grant, award, or other acquisition | 3.34K shares |
| Other acquisition or disposition | 12.5K shares |
|---|---|
| Payment of exercise price or tax liability | 2.54K shares |